HKSE - Delayed Quote HKD

WuXi Biologics (Cayman) Inc. (2269.HK)

18.420

-0.040

(-0.22%)

At close: January 28 at 12:08:04 PM GMT+8

WuXi Biologics to sell Ireland-based vaccine site to MSD for $500m

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

Pharmaceutical Technology 23 days ago

GLDAF

WXXWY
Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager

SAN DIEGO & SHANGHAI, January 07, 2025--Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases, announced today an agreement with WuXi Biologics under which Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics’ proprietary universal multispecific antibody platform WuXiBodyTM. Candid plans to complete IND enabling s

Business Wire 24 days ago

WXIBF

WXXWY
WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an agreement with Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases.

PR Newswire 24 days ago

WXIBF

WXXWY
WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the 2024 Dow Jones Sustainability Indices (DJSI), and given among the top scores for its unremitting efforts and notable achievements in promoting sustainable development.

PR Newswire 29 days ago

WXIBF

WXXWY
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in the "20 Case Examples for 20 Years: Private Sector's Sustainable Development in China" report initiated by the United Nations Global Compact. The company has been invited to UNGC global roadshow and has earned recognition for its effective and dedicated efforts to continue the advancement of green biologics solutions for a he

PR Newswire last month

WXIBF

WXXWY
WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L PPQ Success and HPRA GMP Authorizations

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced major accomplishments at its cutting-edge greenfield site in Dundalk, Ireland. The site has successfully completed multiple 16,000-liter Process Performance Qualification (PPQ) runs at its MFG7 drug substance suite. So far, the site has completed two PPQ runs with 100% success rate. In addition, all three manufacturing facilities received GMP approval fro

PR Newswire last month

WXIBF

WXXWY
WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it will enhance its drug product (DP) capabilities at the company's facility in Leverkusen, Germany, with a new sterile filling line for prefilled syringes (PFS) using isolator technology.

PR Newswire 2 months ago

WXIBF

WXXWY
WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expression system platform. The platform, specialized in non-antibiotic cell line development, employs zinc finger nucleases (ZFN) technology for targeted knockout of the endogenous GS gene in CHO cells.

PR Newswire 3 months ago

WXIBF

WXXWY
WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has received a Platinum Award from The Asset ESG (Environmental, Social and Governance) Corporate Awards for the fourth year in a row. The prestigious honor recognizes the company's unwavering commitment to sustainable practices as well as its effective approaches to driving innovation and efficiency through green technology.

PR Newswire 3 months ago

WXIBF

WXXWY
WuXi Biologics (Cayman) Inc (WXXWY) Half Year 2024 Earnings Call Highlights: Navigating Growth ...

Despite a flat overall revenue, WuXi Biologics (Cayman) Inc (WXXWY) shows resilience with strong non-COVID growth and strategic project acquisitions.

GuruFocus.com 3 months ago

WXXWY
WuXi AppTec, WuXi Biologics surge in Hong Kong as biotech firms put some operations for sale

Shares of WuXi AppTec and WuXi Biologics surged in Hong Kong on Friday, following a report that the two firms are looking to divest some of their operations in the wake of new United States legislation targeting Chinese biotech companies. WuXi AppTec's shares closed up almost 12 per cent to HK$67.10 on Friday, while shares of subsidiary WuXi Biologics rose nearly 15 per cent to HK$21.45. Those gains were made after The Financial Times, citing people familiar with the matter, reported on Thursday

South China Morning Post 3 months ago

WXXWY
WuXi Biologics Included in Hang Seng ESG 50 Index

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has been included in the Hang Seng ESG 50 Index, making it the only pharmaceutical company selected this year. The Index became effective September 9, following the Hang Seng Indexes review results announcement in August.

PR Newswire 4 months ago

WXIBF

WXXWY
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI™ in 2,000L GMP Manufacturing

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has successfully accomplished 2,000L drug substance (DS) GMP manufacturing by utilizing its proprietary ultra-intensified fed-batch bioprocessing platform WuXiUI™. The platform achieved a titer of 18 g/L, a 4-fold increase compared to conventional fed-batch process, demonstrating the high efficiency of WuXiUI™ in improving productivity.

PR Newswire 4 months ago

WXIBF

WXXWY
WuXi Biologics Reports Solid 2024 Interim Results

WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2024 ("Reporting Period").

PR Newswire 5 months ago

WXIBF

WXXWY
WuXi Biologics and Medigene link on T cell engagers for cancer

The collaboration will combine Medigene's advanced TCR generation capabilities with WuXi Biologics' platform.

Pharmaceutical Technology 5 months ago

MDG1.DE

WXXWY
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Medigene AG (Medigene, FSE: MDG1, Prime Standard) today announced that they have entered into a three-year, multi-target strategic partnership to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors. The collaboration combines the respective expertise of each company with Medigene's 3S (sensitiv

PR Newswire 5 months ago

WXIBF

WXXWY
WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that four manufacturing facilities and Suzhou Biosafety Testing Center in China have received Good Manufacturing Practice (GMP) certificates from the European Medicines Agency (EMA), demonstrating the company's commitment to meeting rigorous international industry quality standards across its global network.

PR Newswire 5 months ago

WXIBF

WXXWY
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year the company has been included in the Index for its outstanding sustainability performance.

PR Newswire 6 months ago

WXIBF

WXXWY
US House committee moves quickly to approve bill limiting business with Chinese biotech firms

Bipartisan legislation that would restrict US business with world-leading Chinese biotech companies and their subsidiaries was approved by a House of Representatives committee on Wednesday. The House Committee on Oversight and Accountability passed the bill 40-1. To become law, the bill must pass the full House and Senate, then be signed by the president. The bill, introduced on Friday, would prevent federal agencies from contracting with five Chinese biotech companies - BGI Group, MGI, Complete

South China Morning Post 8 months ago

WXXWY
WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment

WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today published its 2023 Environmental, Social and Governance (ESG) Report, highlighting the company's substantial progress in advancing sustainable development.

PR Newswire 8 months ago

WXIBF

WXXWY

Performance Overview

Return	2269.HK	HANG SENG INDEX
YTD	+3.95%	+0.92%
1-Year	-24.97%	+26.79%
3-Year	-76.14%	-15.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

WuXi Biologics (Cayman) Inc. (2269.HK)

WuXi Biologics to sell Ireland-based vaccine site to MSD for $500m

Candid Therapeutics Enters into Agreement with WuXi Biologics on Trispecific T-cell Engager

WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year

WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection

WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L PPQ Success and HPRA GMP Authorizations

WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line

WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development

WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year

WuXi Biologics (Cayman) Inc (WXXWY) Half Year 2024 Earnings Call Highlights: Navigating Growth ...

WuXi AppTec, WuXi Biologics surge in Hong Kong as biotech firms put some operations for sale

WuXi Biologics Included in Hang Seng ESG 50 Index

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI™ in 2,000L GMP Manufacturing

WuXi Biologics Reports Solid 2024 Interim Results

WuXi Biologics and Medigene link on T cell engagers for cancer

WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers

WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics

WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year

US House committee moves quickly to approve bill limiting business with Chinese biotech firms

WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment

Performance Overview